Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC translocations, with or without BCL2 translocations, have been associated with inferior survival in DLBCL. We investigated whether...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology Jg. 30; H. 28; S. 3452
Hauptverfasser:	Johnson, Nathalie A, Slack, Graham W, Savage, Kerry J, Connors, Joseph M, Ben-Neriah, Susana, Rogic, Sanja, Scott, David W, Tan, King L, Steidl, Christian, Sehn, Laurie H, Chan, Wing C, Iqbal, Javeed, Meyer, Paul N, Lenz, Georg, Wright, George, Rimsza, Lisa M, Valentino, Carlo, Brunhoeber, Patrick, Grogan, Thomas M, Braziel, Rita M, Cook, James R, Tubbs, Raymond R, Weisenburger, Dennis D, Campo, Elias, Rosenwald, Andreas, Ott, German, Delabie, Jan, Holcroft, Christina, Jaffe, Elaine S, Staudt, Louis M, Gascoyne, Randy D
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.10.2012
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Antibodies, Monoclonal, Murine-Derived - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cyclophosphamide - therapeutic use Disease-Free Survival Doxorubicin - therapeutic use Female Gene Expression Profiling Humans Immunohistochemistry Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - genetics Lymphoma, Large B-Cell, Diffuse - mortality Male Middle Aged Prednisone - therapeutic use Prognosis Proto-Oncogene Proteins c-bcl-2 - genetics Proto-Oncogene Proteins c-myc - genetics Rituximab Survival Rate Translocation, Genetic Vincristine - therapeutic use Young Adult
ISSN:	1527-7755, 1527-7755
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!